![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright © 2005, American Society for Microbiology hnRNP K Binds a Core Polypyrimidine Element in the Eukaryotic Translation Initiation Factor 4E (eIF4E) Promoter, and Its Regulation of eIF4E Contributes to Neoplastic Transformation Cancer Research Center at Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114,1 Washington University School of Medicine, Division of Gastroenterology, 660 South Euclid Avenue, St. Louis, Missouri 63110,2 NIA-NIH, LCMB Box 12, 5600 Nathan Shock Drive, Baltimore, Maryland 21224,3 Department of Pediatrics, Harvard Medical School, MassGeneral Hospital for Children, Fruit Street, Boston, Massachusetts 021144 *Corresponding author. Mailing address: Cancer Research Center at Massachusetts General Hospital and Harvard Medical School, 55 Fruit St., Boston, MA 02114. Phone: (617) 726-5707. Fax: (617) 726-8623. E-mail: Schmidt/at/helix.mgh.harvard.edu. Received November 20, 2004; Revised December 23, 2004; Accepted May 2, 2005. This article has been cited by other articles in PMC.Abstract Translation initiation factor eukaryotic translation initiation factor 4E (eIF4E) plays a key role in regulation of cellular proliferation. Its effects on the m7GpppN mRNA cap are critical because overexpression of eIF4E transforms cells, and eIF4E function is rate-limiting for G1 passage. Although we identified eIF4E as a c-Myc target, little else is known about its transcriptional regulation. Previously, we described an element at position −25 (TTACCCCCCCTT) that was critical for eIF4E promoter function. Here we report that this sequence (named 4EBE, for eIF4E basal element) functions as a basal promoter element that binds hnRNP K. The 4EBE is sufficient to replace TATA sequences in a heterologous reporter construct. Interactions between 4EBE and upstream activator sites are position, distance, and sequence dependent. Using DNA affinity chromatography, we identified hnRNP K as a 4EBE-binding protein. Chromatin immunoprecipitation, siRNA interference, and hnRNP K overexpression demonstrate that hnRNP K can regulate eIF4E mRNA. Moreover, hnRNP K increased translation initiation, increased cell division, and promoted neoplastic transformation in an eIF4E-dependent manner. hnRNP K binds the TATA-binding protein, explaining how the 4EBE might replace TATA in the eIF4E promoter. hnRNP K is an unusually diverse regulator of multiple steps in growth regulation because it also directly regulates c-myc transcription, mRNA export, splicing, and translation initiation. eIF4E catalyzes the rate-limiting step in eukaryotic translation and was shown to be the least abundant of all translation initiation factors in cells (27). Although it binds to the 5′ cap structures on all mRNAs, eIF4E must exert specific effects on various mRNAs because it functions as an oncogene in transformation assays (18, 52). Translational control by eIF4E specifically regulates steps in cell proliferation that are frequently abnormal in malignant cells. For example, the yeast mutant expressing a temperature-sensitive eIF4E (cdc33) arrests in G1 at its restrictive temperature (7). eIF4E's transforming function is likely to be clinically significant because eIF4E is overexpressed in a variety of malignant cells and tissues (15, 16, 53, 77). One critical role for eIF4E in oncogenesis may be as the downstream effector of the akt survival pathway that collaborates with various other oncogenes (83, 103). As such, it appears to work in part by preventing apoptotic cell death (54). Whether its overexpression is a cause or an effect of malignant transformation remains an intriguing and important question. In both head and neck tumors, as well as in rare breast cancers, amplifications of the eIF4E gene have been described (37, 92). However, noncytogenetic regulatory events appear to contribute to its overexpression in colon, lung, lymphoma, and bladder cancers (77). The nature of these regulatory events remains unknown. Despite the growing realization of its potential importance in cancer, astonishingly little is known about mechanisms that regulate levels of eIF4E (57). Numerous studies have shown its functional regulation by various signal transduction pathways and by binding to its antagonist, the 4E binding protein (reviewed in references 11 and 15). However, measurements of its quantitative levels in cells have attracted much less attention (101). Early studies that demonstrated serum and heat shock regulation of initiation factors were hampered because eIF4E levels were too low to detect in two-dimensional gels (24-26). Tissue-specific changes in eIF4E mRNA have been demonstrated in Drosophila and zebra fish (31, 39). In mammalian systems, its levels vary during epithelial differentiation and cardiocyte growth (56, 102). Our initial report that serum induces eIF4E mRNA remains a critical demonstration that transcriptional regulation of eIF4E can play an important role in its overall regulation (80). Importantly, the promoter of the eIF4E gene contains two essential E boxes that bind to, and can be regulated by, the MYC oncogene (32, 46). However, an additional site at −25 in the promoter was equally important to the function of the eIF4E promoter (45). Its position at −25, where TATA sequences would be anticipated, suggested that eIF4E might be regulated by a unique basal promoter element. To better understand the regulation of eIF4E in normal and malignant tissues, we sought to further characterize this regulatory motif that we now designate the 4E basal element (4EBE). As in the case of eIF4E, little is known about transcriptional regulation of other translation initiation factors. The abundance of translation initiation factors eIF1 and eIF4A exceeds the abundance of ribosomal proteins; both are therefore among the most abundant proteins in the cell (26, 101). The promoters for both follow the classic paradigm of strong promoters that contain TATA sites (14, 73). The promoters for eIF2α and eIF2β have also been analyzed in some detail. eIF2α and eIF2β are both less abundant than ribosomal proteins. Their promoters lack TATA sequences (9, 42), and they both share a palindromic sequence (TGCGCATGCGCA) that binds nuclear respiratory factor 1 (NRF-1). NRF-1 is thought to coordinate transcriptional regulation of nucleus-encoded respiratory proteins located in the mitochondria (9, 29, 47). Also called α-palindromic binding protein (α-PAL), NRF-1 avidly binds the palindromic sequence in the eIF2α promoter (8, 29). Overexpression of NRF-1 increases eIF2α and net protein synthesis, although it actually inhibits cell division through effects on E2F1 (30). Intriguingly, NRF-1 can heterodimerize with max, and the α-PAL sequence is an alternative-binding site for Myc (4, 30, 80). Finally, an inhibitory sequence in the first intron of eIF2α functions as an initiator (INR) element, and INR elements are repressed by Myc (67, 81, 88). Nuclear run-on experiments first demonstrated a connection between Myc and transcription of translation initiation factors eIF4E and eIF2α (80). Since then, accumulating data have linked Myc regulation to ribosomal proteins and additional translation initiation factors and thereby to growth regulation in the cell (86). The c-Myc target gene database lists 16 translation initiation factors whose potential connections to Myc regulation have been suggested (105). Evidence for this linkage comes from chromatin immunoprecipitation, loss of expression in c-myc-null cells, gain of expression in primary liver cells, and increased expression resulting from conditional increases in Myc function (32, 48, 68, 72). The best evidence for a Myc connection is still found for eIF4E and eIF2α, although the rules associating Myc with regulation of these two factors remain ambiguous (105). Although Myc does not regulate these factors in all circumstances, its regulation of translation initiation is potentially important in cancer biology because a dominant inhibitor of translation initiation blocks transformation by Myc (55). The location of the 4EBE at the site where TATA should be found raises the possibility that it is a functional basal promoter element. Two types of cis-acting DNA elements regulate eukaryotic promoters transcribed by RNA polymerase II genes: (i) basal or core promoter elements located near or at the transcription initiation site and (ii) upstream or regulatory promoter elements that are binding sites for various transcription activators and/or repressors (40). Utilization of the TATA-binding protein (TBP) is common to promoters transcribed by all RNA polymerases (106). TBP is present in a complex called TFIID containing TBP along with various TBP-associated factors (TAFs) (28, 107, 108). Although TBP is generally required for the transcription of most genes, the identification of TBP-related factors TRF1 and TRF2 and a TBP-free, TAF-containing complex, which lacks TBP but contains TAFs, suggests that there are alternative mechanisms by which transcription may be initiated in the case of certain genes (34, 74). Additional basal promoter elements have been identified that can be distinguished from TATA. Seminal work contributed by Smale demonstrated an additional basal element spanning the transcription initiation site that was called the INR element that functions as a TATA equivalent in many TATA-less genes (90). Initiator elements are especially important in cell growth control since they were identified as the δ element in the promoters of ribosomal protein genes (1, 22, 35, 84). Specific DNA-binding proteins, including YY1, TFII-I, USF, and E2F, bind initiator elements (2, 43, 44, 82). In characterizing the eIF4E promoter, we identified protein species of 68 and 97 kDa that bound the 4EBE (45). This element, initially designated LS3 (5′-TTACCCCCCCTT), is highly conserved between mouse, rat, and human eIF4E promoters (45, 56). We first considered that this element might be a classic initiator because of its strategic location, the lack of a TATA, and its pyrimidine richness. However, the element did not cross-compete with known initiator sequences, was not transactivated by YY1, and was not supershifted by antibodies to any known initiator-binding proteins in electrophoretic mobility shift assay (EMSA) experiments (45). Although C-rich it also did not bind SP1 because SP1 oligonucleotides did not cross-compete for binding and an antibody to SP1 did not supershift complexes in EMSA experiments (45). Here we examine the role of this element, which we now designate the 4EBE. We report that this sequence functions as a basal promoter element in reporter gene experiments and binds the transcription factor hnRNP K that is known to interact with TBP (62). We go on to demonstrate that overexpression of hnRNP K causes an eIF4E-dependent cellular transformation that synergizes with Myc, identifying a new regulatory interaction that could play a role in human malignancies overexpressing eIF4E. MATERIALS AND METHODS Plasmids and plasmid construction. The E1bTATA CAT plasmid was used as the starting plasmid for construction of reporter plasmids because it lacks any known elements apart from its simple TATA. The sequence upstream of CAT in this reporter is shown in Fig. Fig.11
For the constructs containing the linker scanning mutations in the eIF4E promoter, the p4ECAT plasmid that contains 403 nucleotides of proximal promoter sequence from the eIF4E genomic clone was used as the parental plasmid (45). In order to generate mutations in the 4EBE site in the native 4E promoter, the QuikChange site-directed mutagenesis kit was used (Stratagene). 5′ and 3′ primers harboring the mutations in the middle of the primers were synthesized and used for the generation of the mutations according to the manufacturer's instructions. The p4ECAT plasmid was used as the template. The various primers used for PCR-induced mutations are summarized in Fig. Fig.11 The expression plasmids pCEP4 (Invitrogen empty vector control [hygromycin selectable]), pCEPmyc (human Myc driven by cytomegalovirus), and pCEP4EBPμ(a constitutive dominant-inhibitory form of the 4E binding protein that blocks eIF4E function) were described previously (55). pcDNA-hnRNP K was created by using the cDNA for hnRNP K from an Image Clone purchased from Invitrogen that was then cloned into pcDNA3.1 (Invitrogen; G418 selectable) by using NotI and XhoI restriction sites. An hnRNP K retroviral expression vector was constructed by cloning the hnRNP K cDNA into the pBABE-puro vector by using an EcoRI-XhoI fragment from pcDNA-hnRNP K. Terminal oligopyrimidine (TOP) reporter plasmids, including rpL32-green fluorescent protein (GFP) and a mutant rpL32-GH containing a C→A mutation in its cap to eliminate TOP function were a generous gift from O. Meyuhas (96). Cells, transfections, and chloramphenicol acetyltransferase (CAT) assays. HeLa cells were obtained from the American Type Culture Collection, Manassas, Va. Adherent cells were grown in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (FCS), antibiotics and l-glutamine. HO15 (myc−/−) and TGR (myc+/+) cells were obtained from John Sedivy (59) and were also grown in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum, antibiotics, and l-glutamine. Rat 1A cells were isolated for their susceptibility to transformation in one step by Myc (93) and were obtained from Chi Dang. For CAT assays, exponentially growing HeLa cells were transfected in 100-mm dishes by using standard calcium phosphate coprecipitations (85). Briefly, HeLa cells were transfected with 10 μg of CAT reporter plasmid and 2 μg of pSVtkhGH plasmid as internal control. Cells were fed with fresh medium 24 h after transfection and harvested for CAT activity 48 h posttransfection by a standard assay (46). The CAT activity in each case was normalized to human growth hormone levels in the media, as determined by using a commercial radioimmunoassay kit (Nichols Institute) according to the manufacturer's instructions. Transfections were typically performed in duplicate and repeated three times. Rat1A cells were transfected by using Lipofectin reagents (Gibco-BRL) with pCEP4, pCEPmyc, and pCEP-4EBPμ, respectively, together with either pcDNA3.1 or pcDNA-hnRNP K as indicated in individual figure legends. Pooled transfectants were selected in the presence of 500 μg of Geneticin and 200 μg of hygromycin/ml. Since all colonies expressed the transfected proteins due to the double selection applied to all transfections, pooled transfectants were used in all studies. Packaged retroviruses expressing hnRNP K or a GFP control were made with the EcoPac retroviral packaging vector; 293T cells were cotransfected with either pBABE-GFP or pBABE-hnRNP K by using standard calcium chloride techniques. Subconfluent HO15 cells were infected with 50% viral supernatants. Two days after infection, puromycin was added at a concentration of 2 μg/ml to select for infected cells, and puromycin selection was continued throughout the remainder of the experiment. After expansion, HO15 cells carrying either pBABE-GFP or pBABE-hnRNP K were seeded in 35-mm plates and allowed to become confluent. They were then serum starved for 48 h; half of the plates were stimulated with 10% fetal bovine serum for 20 h. DNA synthesis was measured by addition of [3H]thymidine (1 μCi of 50 mCi/mmol; MP Biomedicals) for the last 2 h of serum stimulation and is plotted as the mean and standard deviation for three determinations per condition. Cells were harvested by using a previously described method (75). Additional cells were expanded into 100-mm plates for polysomal analysis by the method described below. For hnRNP K siRNA experiments, proliferating TGR or HO15 cells were transfected with 10 nM scrambled control duplex oligonucleotide (Dharmacon, Inc.) containing sense 5′-GCGCGCUUUGUAGGAUUCGtt-3′ and antisense 5′-CGAAUCCUACAAAGCGCGCtt-3′. These transfections were compared to 10 nM small interfering RNA (siRNA) for hnRNP K (Hrpk_1 siRNA; Ambion, Inc.) containing sense 5′-GGAACAAGCCUUUAAAAGAtt-3′ and antisense 5′-UCUUUUAAAGGCUUGUUCCtc-3′. Transfections were accomplished by using Oligofectamine (Invitrogen, Inc.) according to the manufacturer's instructions. mRNA and protein were harvested after 48 h and analyzed for the expression of hnRNP K and eIF4E as described below. Additional siRNAs were used to block eIF4E expression in Rat1A cells. Proliferating Rat1A cells were transfected with 50 nM concentrations of the following siRNA duplexes from Ambion, Inc.: siRNA ID 56229 E1 sense (GGAUGGUAUUGAGCCUAUGtt), E1 antisense (CAUAGGCUCAAUACCAUCCtt); and siRNA ID 56139 E2 sense (GGUGGGCACUCUGGUUUUUtt) and E2 antisense (AAAAACCAGAGUGCCCACCtg). The cells were then compared to a nontargeting siRNA duplex for luciferase containing the following sequences (Dharmacon): nontargeting siRNA #2 sense, 5′-UAAGGCUAUGAAGAGAUACUU-3′; nontargeting siRNA #2 antisense, 5′-PGUAUCUCUUCAUAGCCUUAUU-3′. These experiments were performed by using the same conditions as for the hnRNP K experiments. Protein was harvested after 48 h and analyzed for eIF4E and actin protein as described below. These siRNAs were then transfected into Rat1A cells expressing hnRNP K and transferred into soft agar after 48 h. Soft agar colony formation was evaluated 8 days later. Protein purification and monitoring by Southwestern analysis. Nuclear extracts were prepared from at least 108 of HeLa cells growing in monolayer culture by a modification of the Dignam method (19, 20, 65). The extraction buffer was composed of 0.5% deoxycholate, 1% octyl-β-glucoside, 20 mM HEPES (pH 7.9), 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM dithiothreitol (DTT), and 25% glycerol. The initial crude extract was dialyzed overnight against hydrophobic exchange column buffer [1 M (NH4)2SO4, 20 mM HEPES (pH 7.2), 100 mM KCl, 0.2 mM EDTA, 0.5 mM PMSF, 0.5 mM DTT]. The precipitate resulting from dialysis against the 1 M (NH4)2SO4 was removed by centrifugation at 14,000 rpm for 5 min in a microcentrifuge. The supernatant was loaded on a phenyl Sepharose column and eluted by using a 1 to 0 M (NH4)2SO4 gradient over 10 column volumes. Then, 1-ml fractions were collected and the positive fractions were identified by using aliquots from the fractions in Southwestern analyses as described below. The positive fractions were dialyzed overnight in monoS column loading buffer (50 mM NaCl, 10 mM HEPES [pH 7.4], 5 mM MgCl2, 1 mM EDTA, 1 mM DTT, 0.2 mM PMSF). The loading preparation was cleared by centrifugation, and positive fractions were identified by Southwestern analysis after elution from the monoS column with a 50 to 500 mM NaCl gradient. The monoS-positive fractions were pooled and dialyzed overnight against affinity binding buffer (50 mM NaCl, 5 mM MgCl2, 20 mM HEPES [pH 7.4], 1 mM DTT, 1 mM EDTA, 0.2 mM PMSF, 5% glycerol). Affinity binding to a 1.2 mM concentration of a biotinylated 4EBE trimeric double-stranded oligonucleotide (CTAGATTCCTCTTACCCCCCCTTCTTCCTCTTACCCCCCCTTCTTCCTCTTACCCCCCCTTGG) was performed at 4°C for 20 min in the presence of 0.4 μg of salmon sperm DNA/μl. Next, we added 100 μl of streptavidin beads, and binding continued for an additional 6 h at 4°C with gentle mixing with continuous rotation. The streptavidin beads were then washed extensively with the affinity binding buffer and spun gently, and the bound material was eluted by boiling in standard Laemmli loading buffer. This preparation was run on a 10% denaturing polyacrylamide gel, and a single protein band was identified at 68 kDa by using colloidal blue staining. Southwestern analyses were performed essentially as described previously (38, 89, 94, 100). Nuclear extracts (50 μg) from the indicated cell types were run on 10% denaturing polyacrylamide gels, electroblotted to nitrocellulose for 12 h, and allowed to dry. The filters were then immersed for 10 min in denaturation-renaturation buffer containing 6 M guanidine hydrochloride. Partial renaturation of immobilized proteins was effected by five successive incubations of the filters in buffer containing progressive (twofold) dilutions of guanidine hydrochloride and finally in buffer lacking the denaturant. Filters were blocked with 5% nonfat dry milk in binding buffer (50 mM Tris [pH 7.5], 50 mM NaCl, 1 mM EDTA, 1 mM DTT) and were then washed twice with 0.25% nonfat dry milk in binding buffer. Filters were hybridized in binding buffer containing Klenow-labeled LS3 trimer oligonucleotide probe, 0.25% nonfat dry milk, and 1 μg of sonicated salmon sperm DNA per ml for 60 min at room temperature. Filters were then washed three times with binding buffer containing 0.25% nonfat dry milk alone and dried. DNA-binding assays. HeLa nuclear extracts were obtained and analyzed by using published methods (19, 97). Gel shift activity for 4EBE binding proteins was determined in EMSA binding buffer (25 mM Tris [pH 7.5], 50 mM NaCl, 1 mM EDTA, 200 mM glycine, 0.1% Tween 20, 0.55 mg of bovine serum albumin/ml, 10% glycerol) with 2 ng of poly(dI-dC)/μl as a nonspecific competitor. Complexes formed in binding buffer were resolved on a 4% nondenaturing polyacrylamide gel containing 0.5× TBE (0.045 M Tris-borate [pH 8.0], 0.5 mM EDTA) at 4°C. After labeling with [γ-32P]ATP with polynucleotide kinase, oligonucleotides were purified by polyacrylamide gel electrophoresis. Each binding reaction contained between 0.1 to 0.5 ng of labeled oligonucleotide. Competition experiments were performed by using the indicated molar excess of unlabeled oligonucleotides. Oligonucleotide sequences are provided in the relevant figures. Chromatin immunoprecipitation assays. We evaluated TGR cells during logarithmic growth, at confluence after 72 h in the absence of serum to arrest the cells, and 8 h after serum was added to the growth-arrested cells. Cells grown on 150-mm diameter plates were harvested and resuspended in growth medium. Cross-linking was performed by adding fresh 37% formaldehyde to a final concentration of 1.5%, followed by incubation at room temperature for 15 min with gentle agitation. The reaction was stopped by adding glycine to a final concentration of 0.125 M, followed by incubation for 5 min. Cells were collected by centrifugation at 1,500 × g for 5 min; the pellet was washed twice with ice-cold phosphate-buffered saline (120 mM NaCl, 2.7 mM KCl, 10 mM phosphate buffer [pH 7.4]), washed twice with immunoprecipitation buffer (IP buffer; 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% NP-40, 50 mM Tris-HCl [pH 7.5], 0.5 mM DTT), and then resuspended with IP buffer supplemented with 0.5% sodium dodecyl sulfate (SDS) and protease inhibitor cocktail (Roche). Sonication was performed by Branson Sonifier 250 with a microtip at output 6 with 10-s bursts until the desired DNA fragment sizes were reached. The lysate was then subjected to centrifugation at 12,000 × g for 10 min. The supernatant was collected and diluted at least fivefold with IP buffer. For immunoprecipitation, antibody was added to the lysate, followed by incubation at 4°C for 1 h with agitation. Protein A-Sepharose beads (Amersham) were added to the mixture and further incubated for 1 h. The beads were collected by centrifugation at 1,500 × g for 30 s, washed twice with IP buffer, twice with high-salt IP buffer (500 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.5% NP-40, 50 mM Tris-HCl [pH 7.5], 0.5 mM DTT), washed twice with stringent wash buffer (10 mM Tris-HCl [pH 7.5], 0.25 M LiCl, 0.5% NP-40, 0.5% sodium deoxycholate, 1 mM EDTA), and washed twice with TE buffer (10 mM Tris-HCl, 0.1 mM EDTA). The bound fraction was eluted by incubating the beads in elution buffer (TE with 1% SDS) at 65°C for 10 min. The cross-links were reversed by incubating the eluate at 65°C for at least 6 h. Samples were treated with proteinase K at 37°C for 1 h, phenol-chloroform extracted, and ethanol precipitated. The following primer sets were used in PCRs: pair 1, c-myc promoter (TACTCTACTCCAGCTCTGGAACG, forward) and c-myc promoter (ACCTACGACAGATGAGGTCTGAG, reverse); pair 2, nontranscribed locus AC120715 (ACCAGCCAGTCAGAGTTCAGG, forward) and nontranscribed locus AC120715 (GGTTTCATCATCCCGAGAC, reverse); pair 3, eIF4E promoter (CTCCACTTCCCAGAAGCCTCTTG, forward) and eIF4E promoter (CGGTTCCACAGTCGCCATCTTAG, reverse); and pair 4, 5S rRNA genes (GTCTACGGCCATACCACCCT, forward) and 5S rRNA genes (AAAGCCTACAGCACCCGGTA, reverse). Aliquots of the samples were assayed by PCR at 95°C for 30 s, 59°C for 45 s, and 72°C for 30 s for 35 cycles and then fractionated on an agarose gel. Expression analyses for mRNA and protein. Levels of expression of myc, hnRNP K, eIF4E, and actin mRNAs were analyzed by using total cellular RNA from the indicated transfectants that was size fractionated (10 μg/lane) on formaldehyde agarose gels, transferred to Hybond-N nylon matrices, and cross-linked by using UV light (10). Filters were hybridized in a rapid hybridization solution (Rapidhyb; Amersham) at 65°C with c-myc, hnRNP K, eIF4E, or actin cDNA fragments α32-P labeled by the Klenow reaction by using random priming. For Western analyses, cells were lysed in Laemmli loading buffer. A total of 10 μg of protein sample was subjected to SDS-10% polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane. Membranes were hybridized with anti-hnRNP K (sc-25373; Santa Cruz), anti-eIF4E (BD610270; Becton Dickinson), anti-Myc (SC41; Santa Cruz), or anti-actin (MAB1501R; Calbiochem) as indicated and detected by enhanced chemiluminescence (Amersham). For RNA blots of the polysomal and subpolysomal fractions, RNA was extracted from the polysomal and subpolysomal fractions by using TRIzol reagent, and 50% of the harvested RNA was analyzed by using standard RNA blotting techniques (85). Polysomal profile analysis. One 100-mm diameter plate containing the indicated stable Rat1A transfectants was harvested for each polysomal analysis. Confluent transfectants were harvested and lysed in 300 μl of RSB (10 mM NaCl, 10 mM Tris-HCl [pH 7.4], 15 mM MgCl2) containing 100 μg of heparin/ml, 1.2% Triton X-100, and 0.12% deoxycholate (60, 96). Nuclei were pelleted for 3 min in a microcentrifuge at 4°C. The 300-μl extract was layered over 11.5 ml of a 15 to 45% (wt/wt) sucrose gradient with a 0.5-ml cushion of 45% sucrose. The gradients were centrifuged at 37,000 rpm for 2.5 h in an SW 41 (Beckman) rotor at 4°C. After centrifugation, the A260 was continuously monitored and recorded across the gradient. For the polysomal rpL32 transient reporter experiments, Rat 1A cells were transfected in 100-mm plates with plasmids carrying either the 5′-untranscribed region of rpL32-GFP or the same untranscribed region lacking the consensus 5′-terminal oligopyrimidine element designated rpL32(−1C>A)-GH. Transfected cells were grown to confluence for 72 h, and during the last 24 h cells were grown in medium lacking serum. For RNA blots of the polysomal and subpolysomal fractions, RNA was extracted from the polysomal and subpolysomal fractions by using TRIzol reagent, and 50% of the harvested RNA was probed for the GFP or GH cDNAs in the reporter genes by standard RNA blotting techniques (49). Cell characterization. Protein content per cell was determined by lysis of a known number of cells in ELB lysis buffer and measurement of the protein content of an aliquot of these lysates by using a kit from Bio-Rad. Subconfluent transfectants were labeled with 10 μM bromodeoxyuridine cell-labeling reagent (Amersham Pharmacia) for 30 min and harvested for cell cycle analysis. Cells were fixed in 80% ethanol for at least 1 h, incubated in anti-bromodeoxyuridine antibody (Becton Dickinson) for 30 min and exposed to anti-mouse-fluorescein secondary antibody (Vector Labs) for 30 min. Cells were resuspended in propidium iodide (70 μg/ml) supplemented with RNase A (25 μg/ml) and analyzed. DNA content was measured by using a FACScan cytometer (Becton Dickinson). The mean and standard error were determined for each cell type in two repetitions of experiments with three independent assays per cell type. Clonogenicity of the Rat1A transfectants in soft agar was performed as described previously (93). For the eIF4E siRNA experiments, Rat1A cells expressing hnRNP K were transfected with the nontargeting siRNA #2 from Dharmacon, and the two siRNAs for eIF4E from Ambion; untransfected control Rat1A cells expressing hnRNP K were included in the analysis of soft agar clone formation. Transfection was allowed to proceed for 48 h when the cells were treated with trypsin and replated in the soft agar. Colony numbers were scored 8 days later. For the pCEP4EBPμ experiments, cells were transfected for 48 h and then placed in selection medium for an additional 48 h. They were then transferred to soft agar and colonies were scored 14 days later. RESULTS 4EBE can replace TATA in a heterologous promoter. We previously reported that the eIF4E gene has a unique transcription initiation site despite its lack of known basal promoter elements (46). Using linker scanning mutants of the eIF4E promoter to identify regions that were important for its expression, we found a novel DNA element spanning positions −28 to −16, which we originally designated LS3 (5′-TTACCCCCCCTT), that was crucial for eIF4E expression (45). Due to the strategic location of LS3 approximating that of TATA, we first tested its function as a potential counterpart of a core promoter element. We replaced the TATA-box in the E1bCAT promoter with the element present in LS3 (here renamed 4EBE) and tested it for transcriptional activity in HeLa cells in transient-transfection assays. Placing 4EBE sequences upstream of the CAT reporter resulted in an increase in transcriptional activity equivalent to that of the TATA alone (Fig. (Fig.2A2A 4EBE supports activated transcription. We next evaluated the potential for 4EBE to support activated transcription by placing two binding sites for the activator Sp1 about 10 bases upstream of either TATA or 4EBE in the E1bCAT plasmid. As shown in Fig. Fig.2B,2B Effect of spacing between TATA/4EBE and upstream activators on transcription. Gene expression is regulated by interactions between the trans-acting factors that bind various cis-acting DNA elements in the promoter of a gene. The spacing of cis-acting elements in a promoter plays an important role in determining the ability of the trans-acting factors to interact with each other. In order to test the effect of spacing on the interactions between 4EBE and various upstream activating sequences, we placed two binding sites for Sp1 10 or 30 bases upstream of the TATA or 4EBE in the E1bCAT plasmid and four E-box elements 10 or 43 bases upstream of the E1bTATA or 4EBE (Fig. (Fig.2D).2D The poly(C)-binding transcription factor hnRNP K binds to the 4E-binding element. We purified proteins binding to the 4E-binding element by using a three-step purification procedure that is described in the methods section and included a DNA affinity step (Fig. (Fig.3).3
Nucleotides in 4EBE important for binding and transcription. Known hnRNP K binding sites are remarkable for their polypyrimidine tracks that follow a single purine (Fig. (Fig.4A).4A The myc CT element (CTE) is a six-mer repeat of a core CT element (line B in Fig. Fig.5A)5A
A rabbit polyclonal anti-C-terminal hnRNP K has been shown to immunoprecipitate chromatin complexes containing hnRNP K in inducibly transcribed loci (71). These experiments confirmed the in vivo binding of hnRNP K to the actively transcribed c-myc promoter. Using this same antibody we compared the presence of hnRNP K at the eIF4E promoter to a nontranscribed locus (GenBank accession number AC120715), the 5S rRNA region and to the c-myc promoter (Fig. (Fig.6).6
We transfected constructs expressing myc, hnRNP K, and their combination into Rat 1A cells to evaluate the effect of hnRNP K on eIF4E expression. Pooled transfectants expressing exogenous myc, hnRNP K, and myc plus hnRNP K were analyzed in Northern blots to demonstrate expression of the introduced constructs (Fig. (Fig.7A)7A
Both hnRNP K and eIF4E transform cells (52, 58). To address the potential significance of hnRNP K's regulation of eIF4E, we first compared the transforming potential of each gene in Rat1A transfectants (Fig. (Fig.8).8
Altering eIF4E levels should result in altered rates of translation initiation if hnRNP K's regulation of eIF4E is biologically significant. To evaluate the effect of hnRNP K overexpression on global translation initiation rates, we compared the net quantity of mRNAs contained in the actively translating polysomal fractions of Rat 1A cells overexpressing hnRNP K to those transfected with the vector alone (Fig. (Fig.9A).9A
Last, we sought to determine whether hnRNP K's effects on eIF4E were required for it to transform cells (Fig. (Fig.10).10
We had previously developed a dominant inhibitory form of the 4E binding protein (4EBP) that blocks eIF4E function, which we designated 4EBPμ (55). In that study, 4EBPμ's function was shown to depend on its interactions with eIF4E. We had used that construct to show that eIF4E function was required for Myc transformation. We therefore applied the same approach to confirming the importance of eIF4E function in transformation by hnRNP K (Fig. 10C DISCUSSION Very little is known about the mechanisms underlying the transcriptional regulation of eIF4E and other translation factors despite the fact that the levels of these translation factors play an important role in cellular growth and differentiation and in cancer. Ribosomal protein genes in yeast are regulated as a function of cell growth by DNA factor(s) that are required for activation and coordinated regulation of the whole family of genes coding for the translational apparatus (41, 49). Much less is known about the coordination of synthesis of the growth apparatus of mammalian cells. We were therefore especially interested in characterizing the second element in the eIF4E promoter that was essential for its regulation (45). We had previously demonstrated the required role of the 4EBE by using loss-of-function studies. We therefore evaluated its potential function as a dominant expression element by comparing it to TATA sequences that it appears to replace. This is especially important because basal promoter elements determine the range of transcriptional activators that regulate individual promoters (13). The regulation of eIF4E levels in the cell represents a particular physiologic challenge because the range of normal expression levels of eIF4E is very narrow. With the exception of mRNAs that use internal ribosomal entry sites, eIF4E is required for translation initiation of nearly all mRNAs. It must therefore be expressed ubiquitously in all cells at some undefined minimum level. In contrast, as little as a threefold increase in eIF4E levels is sufficient to derepress translation of at least a subset of mRNAs that can transform cells to a malignant phenotype (7, 91). Using standard reporter gene analyses we show here that the 4EBE can function like TATA to drive reporter gene expression, and its activity can be enhanced by either SP1 or E-box elements (Fig. (Fig.2).2 We identified hnRNP K as a candidate 4EBE binding protein by using standard protein purification methodology. Known interactions of hnRNP K with other promoters, especially c-myc, make it an especially interesting candidate eIF4E regulatory factor. eIF4E is a candidate myc target gene (86), and hnRNP K is one of the most important transcriptional controls of the c-myc promoter (36, 62, 95, 98). The coincidence of hnRNP K regulation of both myc and eIF4E promoters, together with the candidate role of myc in regulating eIF4E, would suggest that complex combinatorial interactions between myc and hnRNP K could be especially important in controlling eIF4E levels. Indeed, we initially showed that the eIF4E regulatory factor increases in cells in direct relationship to myc levels, as might be expected if this factor can regulate myc or is regulated by myc (45). Michelotti et al.'s demonstration that hnRNP K directly interacts with the TBP (62) fits our demonstration that the 4EBE is a core promoter element in the eIF4E promoter. Using EMSAs, additional reporter gene experiments and chromatin immunoprecipitation we demonstrated that the polypyrimidine track in the 4EBE functioned like that in the myc promoter and that both elements functioned identically as DNA-binding elements (Fig. (Fig.44 We then transfected hnRNP K singly and together with Myc to assess the functional significance of hnRNP K as a 4E regulatory factor (Fig. (Fig.7).7 We have previously shown that eIF4E leads to preferential effects on mRNAs that regulate cell division over those that regulate cell growth as one potential explanation for its ability to transform cells (78, 79). This appears to be a mechanism through which cell growth can be coordinated with cell division. We would predict that an eIF4E regulatory factor should phenocopy some effects of eIF4E itself. We therefore first compared transformation by eIF4E to hnRNP K and found that hnRNP K was a somewhat more potent transforming agent at similar levels of eIF4E (Fig. 8A and B hnRNP K is a multifunctional protein known to translationally repress several mRNAs (5), especially those involved in erythrocyte differentiation (33, 69). For example, the DICE element in the 15-lipoxygenase mRNA is silenced by hnRNP K in actively proliferating erythroid precursors. Our findings suggest that, in contrast, hnRNP K should actually enhance translation initiation through increased eIF4E. To resolve these apparent differences, we analyzed global translation initiation rates in hnRNP K-overexpressing cells by using polysomal profiles. We compared the amounts of mRNA in polysomal versus nontranslating fractions in Rat 1A and myc−/− cells expressing increased amounts of hnRNP K to control cells (Fig. 9A and B Finally, we assessed the significance of eIF4E regulation by hnRNP K as a potential contributor to eIF4E's role in malignancy. Averaged over four experiments, hnRNP K more efficiently transformed cells than equivalent amounts of eIF4E expressed on its own (Fig. (Fig.8B).8B Taken together, our data strongly suggest that hnRNP K is a likely candidate eIF4E regulatory factor (4ERF). Purification of hnRNP K by 4EBE binding, demonstration of in vitro-synthesized hnRNP K binding to the 4EBE, demonstration that 4EBE binding is identical to myc CTE binding, regulation of endogenous eIF4E levels by altering hnRNP K levels, and similar cellular behavior of cells overexpressing hnRNP K and eIF4E are all most consistent with this view. hnRNP K is more abundant than most typical transcription factors, and it affects nearly every step in transcription and translation (5). Moreover, it is an unusual transcription factor since it also binds to single-stranded DNA (ssDNA) and single-stranded RNA. Its functions as a candidate transcription factor need to be interpreted in this light. Its binding to TBP is consistent with our proposal that it could act to recruit TBP to the −25 region of the eIF4E promoter. In this view, the 4EBE likely functions as the equivalent of a basal promoter element. In contrast, the presence of a transactivation domain in the hnRNP K N terminus is more consistent with the view that hnRNP K might be acting as another activating protein, although the transactivation domain in hnRNP K is relatively weak (62, 98). Perhaps the most intriguing possibility is that hnRNP K acts indirectly to promote melting of promoter regions by virtue of its preferential binding to ssDNA (97). In this view, hnRNP K acts as a structural activating protein that regulates DNA conformation to promote transcription (6). Such ssDNA binding properties would allow hnRNP K to act on its own without requiring interactions with other parts of the transcription apparatus. ssDNA binding proteins are known to relieve the torsional stress of transcription and so enhance the rate of transcription by this alternative mechanism (50). Although we observed ssDNA binding by hnRNP K to the 4EBE in the eIF4E promoter, it was not as strong as was described for the myc CT-element by the Levens group. Clarification of the relative importance of these three mechanisms to hnRNP K's regulation of eIF4E will require additional exploration of all three mechanisms. Other proteins are also known to bind similar single-stranded polypyrimidine tracks, including several that bind to polypyrimidine elements in the c-myc promoter, and most function both as transactivators and to regulate DNA conformation (64). Any of these additional proteins are potential additional or alternative eIF4E regulatory factor candidates that will require additional future assessments. These proteins include the far upstream sequence binding protein (23), the Pur proteins (3, 87), the cellular nucleic acid binding protein (63), and myc single-stranded proteins (66). Finally, the nature of the 97-kDa protein that we originally identified remains unknown from these initial purification studies (45). Overexpression of hnRNP K produced changes in global translation initiation rates, suggesting the possibility that the polypyrimidine sequence in the eIF4E promoter might be a unifying regulatory motif for additional translation initiation factors. This would be a particularly interesting result, given how little we understand mechanisms by which translation initiation factor synthesis might be coordinated. To evaluate this possibility, we inspected the proximal promoter regions of all 38 human translation initiation factors and found that eight additional promoters contained polypyrimidine stretches analogous to the sequence in eIF4E (Fig. (Fig.11).11
Identification of hnRNP K as the leading 4ERF candidate suggests a variety of additional directions for further study. Its role in human cancers merits further clinical studies to see whether abnormalities in hnRNP K expression, distribution, or signaling function coincide with overexpression of eIF4E (70). The nature of its interactions with Myc will need further elucidation to determine whether it interacts with the regulation of other genes transactivated by Myc. The coincidence of c-Myc binding sites and polypyrimidine stretches in additional translation initiation factors makes this a particularly important issue. Why hnRNP K might play such a prominent role in eIF4E regulation or global regulation of translation initiation is equally interesting. hnRNP K is downstream of multiple signal transduction pathways where integration between signaling cascades and net translation capacity of the cell might provide a significant evolutionary advantage (5). Moreover, hnRNP K has a unique KNS-mediated nuclear importation signal that is dependent on RNA polymerase II transcription (61). This dependence of hnRNP K nuclear localization on polymerase II activity might provide a mechanism to adjust eIF4E and other translation initiation factors to net mRNA copy numbers in the cell. Regardless, the identification of hnRNP K as a 4ERF will certainly guide further explorations of mechanisms that govern eIF4E levels in the cell. Acknowledgments This work was supported by PHS grant RO1-CA63117 (M.L., S.M., L.C., and E.S.). K.K. was supported by NIDDK training grant T32 DK007191. M.R. was supported by NIH NRSA training grant 5T32 CA009216-24. M.J.P. is supported by the Cutaneous Biology Research Center through the Massachusetts General Hospital/Shiseido Co., Ltd., agreement. We thank Marc Wathelet and Tom Maniatis, Department of Molecular and Cellular Biology, Harvard University, for kindly providing the E1bCAT plasmid; Karol Bomsztyk for the generous provision of antibody 54 to the hnRNP K protein; and O. Meyuhas for the 5′TOP translation reporter plasmids. REFERENCES 1. Atchison, M. L., O. Meyuhas, and R. P. Perry. 1989. Localization of transcriptional regulatory elements and nuclear factor binding sites in mouse ribosomal protein gene rpL32. Mol. Cell. Biol. 9:2067-2074. [PubMed] 2. Azizkhan, J. C., D. E. Jensen, A. J. Pierce, and M. Wade. 1993. Transcription from TATA-less promoters: dihydrofolate reductase as a model. Crit. Rev. Eukaryot. Gene Expr. 3:229-254. [PubMed] 3. Bergemann, A. D., Z. W. Ma, and E. M. Johnson. 1992. Sequence of cDNA comprising the human pur gene and sequence-specific single-stranded-DNA-binding properties of the encoded protein. Mol. Cell. Biol. 12:5673-5682. [PubMed] 4. Blackwell, T. K., J. Huang, A. Ma, L. Kretzner, F. W. Alt, R. N. Eisenman, and H. Weintraub. 1993. Binding of myc proteins to canonical and noncanonical DNA sequences. Mol. Cell. Biol. 13:5216-5224. [PubMed] 5. Bomsztyk, K., O. Denisenko, and J. Ostrowski. 2004. hnRNP K: one protein multiple processes. Bioessays 26:629-638. [PubMed] 6. Braddock, D. T., J. L. Baber, D. Levens, and G. M. Clore. 2002. Molecular basis of sequence-specific single-stranded DNA recognition by KH domains: solution structure of a complex between hnRNP K KH3 and single-stranded DNA. EMBO J. 21:3476-3485. [PubMed] 7. Brenner, C., N. Nakayama, M. Goebl, K. Tanaka, A. Toh-e, and K. Matsumoto. 1988. CDC33 encodes mRNA cap-binding protein eIF-4E of Saccharomyces cerevisiae. Mol. Cell. Biol. 8:3556-3559. [PubMed] 8. Chau, C. M., M. J. Evans, and R. C. Scarpulla. 1992. Nuclear respiratory factor 1 activation sites in genes encoding the gamma-subunit of ATP synthase, eukaryotic initiation factor 2α, and tyrosine aminotransferase: specific interaction of purified NRF-1 with multiple target genes. J. Biol. Chem. 267:6999-7006. [PubMed] 9. Chiorini, J. A., S. Miyamoto, S. J. Harkin, and B. Safer. 1999. Genomic cloning and characterization of the human eukaryotic initiation factor-2β promoter. J. Biol. Chem. 274:4195-4201. [PubMed] 10. Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, and W. J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease activity. Biochemistry 18:5294-5299. [PubMed] 11. Clemens, M. J. 2004. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 23:3180-3188. [PubMed] 12. Da Silva, N., A. Bharti, and C. S. Shelley. 2002. hnRNP-K and Pur(alpha) act together to repress the transcriptional activity of the CD43 gene promoter. Blood 100:3536-3544. [PubMed] 13. Das, G., C. S. Hinkley, and W. Herr. 1995. Basal promoter elements as a selective determinant of transcriptional activator function. Nature 374:657-660. [PubMed] 14. Davis, W., Jr., and R. M. Schultz. 1998. Molecular cloning and expression of the mouse translation initiation factor eIF-1A. Nucleic Acids Res. 26:4739-4747. [PubMed] 15. De Benedetti, A., and J. R. Graff. 2004. eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189-3199. [PubMed] 16. De Benedetti, A., and A. L. Harris. 1999. eIF4E expression in tumors: its possible role in progression of malignancies. Int. J. Biochem. Cell Biol. 31:59-72. [PubMed] 17. De Benedetti, A., S. Joshi-Barve, C. Rinker-Schaeffer, and R. E. Rhoads. 1991. Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F. Mol. Cell. Biol. 11:5435-5445. [PubMed] 18. De Benedetti, A., and R. E. Rhoads. 1990. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proc. Natl. Acad. Sci. USA 87:8212-8216. [PubMed] 19. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1475-1489. [PubMed] 20. Dignam, J. D., P. L. Martin, B. S. Shastry, and R. G. Roeder. 1983. Eukaryotic gene transcription with purified components. Methods Enzymol. 101:582-598. [PubMed] 21. Du, Q., I. N. Melnikova, and P. D. Gardner. 1998. Differential effects of heterogeneous nuclear ribonucleoprotein K on Sp1- and Sp3-mediated transcriptional activation of a neuronal nicotinic acetylcholine receptor promoter. J. Biol. Chem. 273:19877-19883. [PubMed] 22. Dudov, K. P., and R. P. Perry. 1986. Properties of a mouse ribosomal protein promoter. Proc. Natl. Acad. Sci. USA 83:8545-8549. [PubMed] 23. Duncan, R., L. Bazar, G. Michelotti, T. Tomonaga, H. Krutzsch, M. Avigan, and D. Levens. 1994. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev. 8:465-480. [PubMed] 24. Duncan, R., and J. W. Hershey. 1984. Heat shock-induced translational alterations in HeLa cells. Initiation factor modifications and the inhibition of translation. J. Biol. Chem. 259:11882-11889. [PubMed] 25. Duncan, R., and J. W. Hershey. 1983. Identification and quantitation of levels of protein synthesis initiation factors in crude HeLa cell lysates by two-dimensional polyacrylamide gel electrophoresis. J. Biol. Chem. 258:7228-7235. [PubMed] 26. Duncan, R., and J. W. Hershey. 1985. Regulation of initiation factors during translational repression caused by serum depletion: abundance, synthesis, and turnover rates. J. Biol. Chem. 260:5486-5492. [PubMed] 27. Duncan, R., S. C. Milburn, and J. W. Hershey. 1987. Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control: heat shock effects on eIF-4F. J. Biol. Chem. 262:380-388. [PubMed] 28. Dynlacht, B. D., T. Hoey, and R. Tjian. 1991. Isolation of coactivators associated with the TATA-binding protein that mediate transcriptional activation. Cell 66:563-576. [PubMed] 29. Efiok, B. J., J. A. Chiorini, and B. Safer. 1994. A key transcription factor for eukaryotic initiation factor-2 alpha is strongly homologous to developmental transcription factors and may link metabolic genes to cellular growth and development. J. Biol. Chem. 269:18921-18930. [PubMed] 30. Efiok, B. J., and B. Safer. 2000. Transcriptional regulation of E2F-1 and eIF-2 genes by alpha-pal: a potential mechanism for coordinated regulation of protein synthesis, growth, and the cell cycle. Biochim. Biophys. Acta 1495:51-68. [PubMed] 31. Fahrenkrug, S. C., M. O. Dahlquist, K. J. Clark, and P. B. Hackett. 1999. Dynamic and tissue-specific expression of eIF4E during zebra fish embryogenesis. Differentiation 65:191-201. [PubMed] 32. Fernandez, P. C., S. R. Frank, L. Wang, M. Schroeder, S. Liu, J. Greene, A. Cocito, and B. Amati. 2003. Genomic targets of the human c-Myc protein. Genes Dev. 17:1115-1129. [PubMed] 33. Habelhah, H., K. Shah, L. Huang, A. Ostareck-Lederer, A. L. Burlingame, K. M. Shokat, M. W. Hentze, and Z. Ronai. 2001. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat. Cell Biol. 3:325-330. [PubMed] 34. Hansen, S. K., S. Takada, R. H. Jacobson, J. T. Lis, and R. Tjian. 1997. Transcription properties of a cell type-specific TATA-binding protein, TRF. Cell 91:71-83. [PubMed] 35. Hariharan, N., D. E. Kelley, and R. P. Perry. 1989. Equipotent mouse ribosomal protein promoters have a similar architecture that includes internal sequence elements. Genes Dev. 3:1789-1800. [PubMed] 36. Hay, N., J. M. Bishop, and D. Levens. 1987. Regulatory elements that modulate expression of human c-myc. Genes Dev. 1:659-671. [PubMed] 37. Haydon, M. S., J. D. Googe, D. S. Sorrells, G. E. Ghali, and B. D. Li. 2000. Progression of eIF4e gene amplification and overexpression in benign and malignant tumors of the head and neck. Cancer 88:2803-2810. [PubMed] 38. Hendrickson, W., and R. Schleif. 1985. A dimer of AraC protein contacts three adjacent major groove regions of the araI DNA site. Proc. Natl. Acad. Sci. USA 82:3129-3133. [PubMed] 39. Hernandez, G., R. Diez del Corral, J. Santoyo, S. Campuzano, and J. M. Sierra. 1997. Localization, structure and expression of the gene for translation initiation factor eIF-4E from Drosophila melanogaster. Mol. Gen. Genet. 253:624-633. [PubMed] 40. Hochheimer, A., and R. Tjian. 2003. Diversified transcription initiation complexes expand promoter selectivity and tissue-specific gene expression. Genes Dev. 17:1309-1320. [PubMed] 41. Huet, J., P. Cottrelle, M. Cool, M. L. Vignais, D. Thiele, C. Marck, J. M. Buhler, A. Sentenac, and P. Fromageot. 1985. A general upstream binding factor for genes of the yeast translational apparatus. EMBO J. 4:3539-3547. [PubMed] 42. Humbelin, M., B. Safer, J. A. Chiorini, J. W. Hershey, and R. B. Cohen. 1989. Isolation and characterization of the promoter and flanking regions of the gene encoding the human protein-synthesis-initiation factor 2 alpha. Gene 81:315-324. [PubMed] 43. Hyde-DeRuyscher, R. P., E. Jennings, and T. Shenk. 1995. DNA binding sites for the transcriptional activator/repressor YY1. Nucleic Acids Res. 23:4457-4465. [PubMed] 44. Javahery, R., A. Khachi, K. Lo, B. Zenzie-Gregory, and S. T. Smale. 1994. DNA sequence requirements for transcriptional initiator activity in mammalian cells. Mol. Cell. Biol. 14:116-127. [PubMed] 45. Johnston, K. A., M. Polymenis, S. Wang, J. Branda, and E. V. Schmidt. 1998. Novel regulatory factors interacting with the promoter of the gene encoding the mRNA cap binding protein (eIF4E) and their function in growth regulation. Mol. Cell. Biol. 18:5621-5633. [PubMed] 46. Jones, R. M., J. Branda, K. A. Johnston, M. Polymenis, M. Gadd, A. Rustgi, L. Callanan, and E. V. Schmidt. 1996. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol. Cell. Biol. 16:4754-4764. [PubMed] 47. Kelly, D. P., and R. C. Scarpulla. 2004. Transcriptional regulatory circuits controlling mitochondrial biogenesis and function. Genes Dev. 18:357-368. [PubMed] 48. Kim, S., Q. Li, C. V. Dang, and L. A. Lee. 2000. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. Proc. Natl. Acad. Sci. USA 97:11198-11202. [PubMed] 49. Klein, C., and K. Struhl. 1994. Protein kinase A mediates growth-regulated expression of yeast ribosomal protein genes by modulating RAP1 transcriptional activity. Mol. Cell. Biol. 14:1920-1928. [PubMed] 50. Kouzine, F., J. Liu, S. Sanford, H. J. Chung, and D. Levens. 2004. The dynamic response of upstream DNA to transcription-generated torsional stress. Nat. Struct. Mol. Biol. 11:1092-1100. [PubMed] 51. Lacroix, L., H. Lienard, E. Labourier, M. Djavaheri-Mergny, J. Lacoste, H. Leffers, J. Tazi, C. Helene, and J. L. Mergny. 2000. Identification of two human nuclear proteins that recognize the cytosine-rich strand of human telomeres in vitro. Nucleic Acids Res. 28:1564-1575. [PubMed] 52. Lazaris-Karatzas, A., K. S. Montine, and N. Sonenberg. 1990. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 345:544-547. [PubMed] 53. Li, B. D., L. Liu, M. Dawson, and A. De Benedetti. 1997. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79:2385-2390. [PubMed] 54. Li, S., D. M. Perlman, M. S. Peterson, D. Burrichter, S. Avdulov, V. A. Polunovsky, and P. B. Bitterman. 2004. Translation initiation factor 4E blocks endoplasmic reticulum-mediated apoptosis. J. Biol. Chem. 279:21312-21317. [PubMed] 55. Lynch, M., C. Fitzgerald, K. A. Johnston, S. Wang, and E. V. Schmidt. 2004. Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth. J. Biol. Chem. 279:3327-3339. [PubMed] 56. Makhlouf, A. A., A. M. Namboodiri, and P. J. McDermott. 2001. Transcriptional regulation of the rat eIF4E gene in cardiac muscle cells: the role of specific elements in the promoter region. Gene 267:1-12. [PubMed] 57. Mamane, Y., E. Petroulakis, L. Rong, K. Yoshida, L. W. Ler, and N. Sonenberg. 2004. eIF4E-from translation to transformation. Oncogene 23:3172-3179. [PubMed] 58. Mandal, M., R. Vadlamudi, D. Nguyen, R. A. Wang, L. Costa, R. Bagheri-Yarmand, J. Mendelsohn, and R. Kumar. 2001. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem. 276:9699-9704. [PubMed] 59. Mateyak, M. K., A. J. Obaya, S. Adachi, and J. M. Sedivy. 1997. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 8:1039-1048. [PubMed] 60. Meyuhas, O., Y. Blierman, P. Pierandrei-Amaldi, and F. Amaldi. 1996. Analysis of polysomal RNA, p. 65-81. In P. Krieg (ed.), A laboratory guide to RNA: isolation, analysis and synthesis. Wiley-Liss, New York, N.Y. 61. Michael, W. M., P. S. Eder, and G. Dreyfuss. 1997. The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein. EMBO J. 16:3587-3598. [PubMed] 62. Michelotti, E. F., G. A. Michelotti, A. I. Aronsohn, and D. Levens. 1996. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol. Cell. Biol. 16:2350-2360. [PubMed] 63. Michelotti, E. F., T. Tomonaga, H. Krutzsch, and D. Levens. 1995. Cellular nucleic acid binding protein regulates the CT element of the human c-myc protooncogene. J. Biol. Chem. 270:9494-9499. [PubMed] 64. Michelotti, G. A., E. F. Michelotti, A. Pullner, R. C. Duncan, D. Eick, and D. Levens. 1996. Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo. Mol. Cell. Biol. 16:2656-2669. [PubMed] 65. Miltenberger, R. J., K. A. Sukow, and P. J. Farnham. 1995. An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol. Cell. Biol. 15:2527-2535. [PubMed] 66. Negishi, Y., Y. Nishita, Y. Saegusa, I. Kakizaki, I. Galli, F. Kihara, K. Tamai, N. Miyajima, S. M. Iguchi-Ariga, and H. Ariga. 1994. Identification and cDNA cloning of single-stranded DNA binding proteins that interact with the region upstream of the human c-myc gene. Oncogene 9:1133-1143. [PubMed] 67. Noguchi, M., S. Miyamoto, T. A. Silverman, and B. Safer. 1994. Characterization of an antisense Inr element in the eIF-2 alpha gene. J. Biol. Chem. 269:29161-29167. [PubMed] 68. O'Connell, B. C., A. F. Cheung, C. P. Simkevich, W. Tam, X. Ren, M. K. Mateyak, and J. M. Sedivy. 2003. A large scale genetic analysis of c-Myc-regulated gene expression patterns. J. Biol. Chem. 278:12563-12573. [PubMed] 69. Ostareck-Lederer, A., D. H. Ostareck, C. Cans, G. Neubauer, K. Bomsztyk, G. Superti-Furga, and M. W. Hentze. 2002. c-Src-mediated phosphorylation of hnRNP K drives translational activation of specifically silenced mRNAs. Mol. Cell. Biol. 22:4535-4543. [PubMed] 70. Ostrowski, J., and K. Bomsztyk. 2003. Nuclear shift of hnRNP K protein in neoplasms and other states of enhanced cell proliferation. Br. J. Cancer 89:1493-1501. [PubMed] 71. Ostrowski, J., Y. Kawata, D. S. Schullery, O. N. Denisenko, and K. Bomsztyk. 2003. Transient recruitment of the hnRNP K protein to inducibly transcribed gene loci. Nucleic Acids Res. 31:3954-3962. [PubMed] 72. Qi, Y., M. A. Gregory, Z. Li, J. P. Brousal, K. West, and S. R. Hann. 2004. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431:712-717. [PubMed] 73. Quinn, C. M., A. P. Wiles, T. El-Shanawany, I. Catchpole, T. Alnadaf, M. J. Ford, S. Gordon, and D. R. Greaves. 1999. The human eukaryotic initiation factor 4AI gene (EIF4A1) contains multiple regulatory elements that direct high-level reporter gene expression in mammalian cell lines. Genomics 62:468-476. [PubMed] 74. Rabenstein, M. D., S. Zhou, J. T. Lis, and R. Tjian. 1999. TATA box-binding protein (TBP)-related factor 2 (TRF2), a third member of the TBP family. Proc. Natl. Acad. Sci. USA 96:4791-4796. [PubMed] 75. Ravitz, M. J., S. Yan, K. D. Herr, and C. E. Wenner. 1995. Transforming growth factor beta-induced activation of cyclin E-cdk2 kinase and down-regulation of p27Kip1 in C3H 10T1/2 mouse fibroblasts. Cancer Res. 55:1413-1416. [PubMed] 76. Ritchie, S. A., M. K. Pasha, D. J. Batten, R. K. Sharma, D. J. Olson, A. R. Ross, and K. Bonham. 2003. Identification of the SRC pyrimidine-binding protein (SPy) as hnRNP K: implications in the regulation of SRC1A transcription. Nucleic Acids Res. 31:1502-1513. [PubMed] 77. Rosenwald, I. B. 2004. The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 23:3230-3247. [PubMed] 78. Rosenwald, I. B., R. Kaspar, D. Rousseau, L. Gehrke, P. Leboulch, J. J. Chen, E. V. Schmidt, N. Sonenberg, and I. M. London. 1995. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and posttranscriptional levels. J. Biol. Chem. 270:21176-21180. [PubMed] 79. Rosenwald, I. B., A. Lazaris-Karatzas, N. Sonenberg, and E. V. Schmidt. 1993. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol. Cell. Biol. 13:7358-7363. [PubMed] 80. Rosenwald, I. B., D. B. Rhoads, L. D. Callanan, K. J. Isselbacher, and E. V. Schmidt. 1993. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc. Natl. Acad. Sci. USA 90:6175-6178. [PubMed] 81. Roy, A. L., C. Carruthers, T. Gutjahr, and R. G. Roeder. 1993. Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature 365:359-361. [PubMed] 82. Roy, A. L., H. Du, P. D. Gregor, C. D. Novina, E. Martinez, and R. G. Roeder. 1997. Cloning of an inr- and E-box-binding protein, TFII-I, that interacts physically and functionally with USF1. EMBO J. 16:7091-7104. [PubMed] 83. Ruggero, D., L. Montanaro, L. Ma, W. Xu, P. Londei, C. Cordon-Cardo, and P. P. Pandolfi. 2004. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 10:484-486. [PubMed] 84. Safrany, G., and R. P. Perry. 1995. The relative contributions of various transcription factors to the overall promoter strength of the mouse ribosomal protein L30 gene. Eur. J. Biochem. 230:1066-1072. [PubMed] 85. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 86. Schmidt, E. V. 2004. The role of c-myc in regulation of translation initiation. Oncogene 23:3217-3221. [PubMed] 87. Shelley, C. S., J. M. Teodoridis, H. Park, O. C. Farokhzad, E. P. Bottinger, and M. A. Arnaout. 2002. During differentiation of the monocytic cell line U937, Pur alpha mediates induction of the CD11c beta 2 integrin gene promoter. J. Immunol. 168:3887-3893. [PubMed] 88. Silverman, T. A., M. Noguchi, and B. Safer. 1992. Role of sequences within the first intron in the regulation of expression of eukaryotic initiation factor 2 alpha. J. Biol. Chem. 267:9738-9742. [PubMed] 89. Singh, H., J. H. LeBowitz, A. S. Baldwin, Jr., and P. A. Sharp. 1988. Molecular cloning of an enhancer binding protein: isolation by screening of an expression library with a recognition site DNA. Cell 52:415-423. [PubMed] 90. Smale, S. T. 1997. Transcription initiation from TATA-less promoters within eukaryotic protein-coding genes. Biochim. Biophys. Acta 1351:73-88. [PubMed] 91. Smith, M. R., M. Jaramillo, Y. L. Liu, T. E. Dever, W. C. Merrick, H. F. Kung, and N. Sonenberg. 1990. Translation initiation factors induce DNA synthesis and transform NIH 3T3 cells. New Biol. 2:648-654. [PubMed] 92. Sorrells, D. L., D. R. Black, C. Meschonat, R. Rhoads, A. De Benedetti, M. Gao, B. J. Williams, and B. D. Li. 1998. Detection of eIF4E gene amplification in breast cancer by competitive PCR. Ann. Surg. Oncol. 5:232-237. [PubMed] 93. Stone, J., T. de Lange, G. Ramsay, E. Jakobovits, J. M. Bishop, H. Varmus, and W. Lee. 1987. Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol. Cell. Biol. 7:1697-1709. [PubMed] 94. Swick, A. G., and M. D. Lane. 1992. Identification of a transcriptional repressor down-regulated during preadipocyte differentiation. Proc. Natl. Acad. Sci. USA 89:7895-7899. [PubMed] 95. Takimoto, M., T. Tomonaga, M. Matunis, M. Avigan, H. Krutzsch, G. Dreyfuss, and D. Levens. 1993. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter, in vitro. J. Biol. Chem. 268:18249-18258. [PubMed] 96. Tang, H., E. Hornstein, M. Stolovich, G. Levy, M. Livingstone, D. Templeton, J. Avruch, and O. Meyuhas. 2001. Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol. Cell. Biol. 21:8671-8683. [PubMed] 97. Tomonaga, T., and D. Levens. 1996. Activating transcription from single stranded DNA. Proc. Natl. Acad. Sci. USA 93:5830-5835. [PubMed] 98. Tomonaga, T., and D. Levens. 1995. Heterogeneous nuclear ribonucleoprotein K is a DNA-binding transactivator. J. Biol. Chem. 270:4875-4881. [PubMed] 99. Van Seuningen, I., J. Ostrowski, and K. Bomsztyk. 1995. Description of an IL-1-responsive kinase that phosphorylates the K protein. Enhancement of phosphorylation by selective DNA and RNA motifs. Biochemistry 34:5644-5650. [PubMed] 100. Vinson, C. R., K. L. LaMarco, P. F. Johnson, W. H. Landschulz, and S. L. McKnight. 1988. In situ detection of sequence-specific DNA binding activity specified by a recombinant bacteriophage. Genes Dev. 2:801-806. [PubMed] 101. von der Haar, T., and J. E. McCarthy. 2002. Intracellular translation initiation factor levels in Saccharomyces cerevisiae and their role in cap-complex function. Mol. Microbiol. 46:531-544. [PubMed] 102. Walsh, D., P. Meleady, B. Power, S. J. Morley, and M. Clynes. 2003. Increased levels of the translation initiation factor eIF4E in differentiating epithelial lung tumor cell lines. Differentiation 71:126-134. [PubMed] 103. Wendel, H. G., E. De Stanchina, J. S. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, and S. W. Lowe. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332-337. [PubMed] 104. Wheeler, D. L., D. M. Church, R. Edgar, S. Federhen, W. Helmberg, T. L. Madden, J. U. Pontius, G. D. Schuler, L. M. Schriml, E. Sequeira, T. O. Suzek, T. A. Tatusova, and L. Wagner. 2004. Database resources of the National Center for Biotechnology Information: update. Nucleic Acids Res. 32(database issue):D35-D40. [PubMed] 105. Zeller, K. I., A. G. Jegga, B. J. Aronow, K. A. O'Donnell, and C. V. Dang. 2003. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 4:R69. [PubMed] 106. Zenzie-Gregory, B., A. Khachi, I. P. Garraway, and S. T. Smale. 1993. Mechanism of initiator-mediated transcription: evidence for a functional interaction between the TATA-binding protein and DNA in the absence of a specific recognition sequence. Mol. Cell. Biol. 13:3841-3849. [PubMed] 107. Zhou, Q., T. G. Boyer, and A. J. Berk. 1993. Factors (TAFs) required for activated transcription interact with TATA box-binding protein conserved core domain. Genes Dev. 7:180-187. [PubMed] 108. Zhou, Q., P. M. Lieberman, T. G. Boyer, and A. J. Berk. 1992. Holo-TFIID supports transcriptional stimulation by diverse activators and from a TATA-less promoter. Genes Dev. 6:1964-1974. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
J Biol Chem. 1987 Jan 5; 262(1):380-8.
[J Biol Chem. 1987]Proc Natl Acad Sci U S A. 1990 Nov; 87(21):8212-6.
[Proc Natl Acad Sci U S A. 1990]Nature. 1990 Jun 7; 345(6275):544-7.
[Nature. 1990]Mol Cell Biol. 1988 Aug; 8(8):3556-9.
[Mol Cell Biol. 1988]Oncogene. 2004 Apr 19; 23(18):3189-99.
[Oncogene. 2004]Int J Biochem Cell Biol. 1999 Jan; 31(1):59-72.
[Int J Biochem Cell Biol. 1999]Cancer. 1997 Jun 15; 79(12):2385-90.
[Cancer. 1997]Oncogene. 2004 Apr 19; 23(18):3230-47.
[Oncogene. 2004]Nat Med. 2004 May; 10(5):484-6.
[Nat Med. 2004]Oncogene. 2004 Apr 19; 23(18):3172-9.
[Oncogene. 2004]Oncogene. 2004 Apr 19; 23(18):3180-8.
[Oncogene. 2004]Oncogene. 2004 Apr 19; 23(18):3189-99.
[Oncogene. 2004]Mol Microbiol. 2002 Oct; 46(2):531-44.
[Mol Microbiol. 2002]J Biol Chem. 1984 Oct 10; 259(19):11882-9.
[J Biol Chem. 1984]J Biol Chem. 1985 May 10; 260(9):5486-92.
[J Biol Chem. 1985]Mol Microbiol. 2002 Oct; 46(2):531-44.
[Mol Microbiol. 2002]Nucleic Acids Res. 1998 Oct 15; 26(20):4739-47.
[Nucleic Acids Res. 1998]Genomics. 1999 Dec 15; 62(3):468-76.
[Genomics. 1999]J Biol Chem. 1999 Feb 12; 274(7):4195-201.
[J Biol Chem. 1999]Proc Natl Acad Sci U S A. 1993 Jul 1; 90(13):6175-8.
[Proc Natl Acad Sci U S A. 1993]Oncogene. 2004 Apr 19; 23(18):3217-21.
[Oncogene. 2004]Genome Biol. 2003; 4(10):R69.
[Genome Biol. 2003]Genes Dev. 2003 May 1; 17(9):1115-29.
[Genes Dev. 2003]Proc Natl Acad Sci U S A. 2000 Oct 10; 97(21):11198-202.
[Proc Natl Acad Sci U S A. 2000]Genes Dev. 2003 Jun 1; 17(11):1309-20.
[Genes Dev. 2003]Mol Cell Biol. 1993 Jul; 13(7):3841-9.
[Mol Cell Biol. 1993]Cell. 1991 Aug 9; 66(3):563-76.
[Cell. 1991]Genes Dev. 1993 Feb; 7(2):180-7.
[Genes Dev. 1993]Genes Dev. 1992 Oct; 6(10):1964-74.
[Genes Dev. 1992]Mol Cell Biol. 1998 Oct; 18(10):5621-33.
[Mol Cell Biol. 1998]Gene. 2001 Apr 4; 267(1):1-12.
[Gene. 2001]Mol Cell Biol. 1996 May; 16(5):2350-60.
[Mol Cell Biol. 1996]Mol Cell Biol. 1998 Oct; 18(10):5621-33.
[Mol Cell Biol. 1998]J Biol Chem. 2004 Jan 30; 279(5):3327-39.
[J Biol Chem. 2004]Mol Cell Biol. 2001 Dec; 21(24):8671-83.
[Mol Cell Biol. 2001]Cell Growth Differ. 1997 Oct; 8(10):1039-48.
[Cell Growth Differ. 1997]Mol Cell Biol. 1987 May; 7(5):1697-709.
[Mol Cell Biol. 1987]Mol Cell Biol. 1996 Sep; 16(9):4754-64.
[Mol Cell Biol. 1996]Cancer Res. 1995 Apr 1; 55(7):1413-6.
[Cancer Res. 1995]Nucleic Acids Res. 1983 Mar 11; 11(5):1475-89.
[Nucleic Acids Res. 1983]Methods Enzymol. 1983; 101():582-98.
[Methods Enzymol. 1983]Mol Cell Biol. 1995 May; 15(5):2527-35.
[Mol Cell Biol. 1995]Proc Natl Acad Sci U S A. 1985 May; 82(10):3129-33.
[Proc Natl Acad Sci U S A. 1985]Cell. 1988 Feb 12; 52(3):415-23.
[Cell. 1988]Proc Natl Acad Sci U S A. 1992 Sep 1; 89(17):7895-9.
[Proc Natl Acad Sci U S A. 1992]Genes Dev. 1988 Jul; 2(7):801-6.
[Genes Dev. 1988]J Biol Chem. 1995 Mar 3; 270(9):4875-81.
[J Biol Chem. 1995]Nucleic Acids Res. 1983 Mar 11; 11(5):1475-89.
[Nucleic Acids Res. 1983]Proc Natl Acad Sci U S A. 1996 Jun 11; 93(12):5830-5.
[Proc Natl Acad Sci U S A. 1996]Biochemistry. 1979 Nov 27; 18(24):5294-9.
[Biochemistry. 1979]Mol Cell Biol. 2001 Dec; 21(24):8671-83.
[Mol Cell Biol. 2001]Mol Cell Biol. 1994 Mar; 14(3):1920-8.
[Mol Cell Biol. 1994]Mol Cell Biol. 1987 May; 7(5):1697-709.
[Mol Cell Biol. 1987]Mol Cell Biol. 1996 Sep; 16(9):4754-64.
[Mol Cell Biol. 1996]Mol Cell Biol. 1998 Oct; 18(10):5621-33.
[Mol Cell Biol. 1998]Genes Dev. 1987 Sep; 1(7):659-71.
[Genes Dev. 1987]Mol Cell Biol. 1996 May; 16(5):2350-60.
[Mol Cell Biol. 1996]J Biol Chem. 1993 Aug 25; 268(24):18249-58.
[J Biol Chem. 1993]J Biol Chem. 1995 Mar 3; 270(9):4875-81.
[J Biol Chem. 1995]Mol Cell Biol. 1996 Sep; 16(9):4754-64.
[Mol Cell Biol. 1996]J Biol Chem. 1995 Mar 3; 270(9):4875-81.
[J Biol Chem. 1995]EMBO J. 2002 Jul 1; 21(13):3476-85.
[EMBO J. 2002]Nat Struct Mol Biol. 2004 Nov; 11(11):1092-100.
[Nat Struct Mol Biol. 2004]Proc Natl Acad Sci U S A. 1996 Jun 11; 93(12):5830-5.
[Proc Natl Acad Sci U S A. 1996]Nucleic Acids Res. 2003 Jul 15; 31(14):3954-62.
[Nucleic Acids Res. 2003]Nature. 1990 Jun 7; 345(6275):544-7.
[Nature. 1990]J Biol Chem. 2001 Mar 30; 276(13):9699-704.
[J Biol Chem. 2001]J Biol Chem. 2004 Jan 30; 279(5):3327-39.
[J Biol Chem. 2004]Proc Natl Acad Sci U S A. 1990 Nov; 87(21):8212-6.
[Proc Natl Acad Sci U S A. 1990]Mol Cell Biol. 1991 Nov; 11(11):5435-45.
[Mol Cell Biol. 1991]J Biol Chem. 2004 Jan 30; 279(5):3327-39.
[J Biol Chem. 2004]J Biol Chem. 2004 Jan 30; 279(5):3327-39.
[J Biol Chem. 2004]EMBO J. 1985 Dec 16; 4(13A):3539-47.
[EMBO J. 1985]Mol Cell Biol. 1994 Mar; 14(3):1920-8.
[Mol Cell Biol. 1994]Mol Cell Biol. 1998 Oct; 18(10):5621-33.
[Mol Cell Biol. 1998]Nature. 1995 Apr 13; 374(6523):657-60.
[Nature. 1995]Mol Cell Biol. 1988 Aug; 8(8):3556-9.
[Mol Cell Biol. 1988]New Biol. 1990 Jul; 2(7):648-54.
[New Biol. 1990]Genes Dev. 2003 Jun 1; 17(11):1309-20.
[Genes Dev. 2003]Oncogene. 2004 Apr 19; 23(18):3217-21.
[Oncogene. 2004]Genes Dev. 1987 Sep; 1(7):659-71.
[Genes Dev. 1987]Mol Cell Biol. 1996 May; 16(5):2350-60.
[Mol Cell Biol. 1996]J Biol Chem. 1993 Aug 25; 268(24):18249-58.
[J Biol Chem. 1993]J Biol Chem. 1995 Mar 3; 270(9):4875-81.
[J Biol Chem. 1995]Cell Growth Differ. 1997 Oct; 8(10):1039-48.
[Cell Growth Differ. 1997]J Biol Chem. 1995 Sep 8; 270(36):21176-80.
[J Biol Chem. 1995]Mol Cell Biol. 1993 Dec; 13(12):7358-63.
[Mol Cell Biol. 1993]Bioessays. 2004 Jun; 26(6):629-38.
[Bioessays. 2004]Nat Cell Biol. 2001 Mar; 3(3):325-30.
[Nat Cell Biol. 2001]Mol Cell Biol. 2002 Jul; 22(13):4535-43.
[Mol Cell Biol. 2002]J Biol Chem. 2004 Jan 30; 279(5):3327-39.
[J Biol Chem. 2004]Bioessays. 2004 Jun; 26(6):629-38.
[Bioessays. 2004]Mol Cell Biol. 1996 May; 16(5):2350-60.
[Mol Cell Biol. 1996]J Biol Chem. 1995 Mar 3; 270(9):4875-81.
[J Biol Chem. 1995]Proc Natl Acad Sci U S A. 1996 Jun 11; 93(12):5830-5.
[Proc Natl Acad Sci U S A. 1996]EMBO J. 2002 Jul 1; 21(13):3476-85.
[EMBO J. 2002]Br J Cancer. 2003 Oct 20; 89(8):1493-501.
[Br J Cancer. 2003]Bioessays. 2004 Jun; 26(6):629-38.
[Bioessays. 2004]EMBO J. 1997 Jun 16; 16(12):3587-98.
[EMBO J. 1997]Nucleic Acids Res. 2003 Mar 1; 31(5):1502-13.
[Nucleic Acids Res. 2003]Blood. 2002 Nov 15; 100(10):3536-44.
[Blood. 2002]J Biol Chem. 1998 Jul 31; 273(31):19877-83.
[J Biol Chem. 1998]Nucleic Acids Res. 2000 Apr 1; 28(7):1564-75.
[Nucleic Acids Res. 2000]J Immunol. 2002 Apr 15; 168(8):3887-93.
[J Immunol. 2002]J Biol Chem. 1993 Aug 25; 268(24):18249-58.
[J Biol Chem. 1993]Biochemistry. 1995 Apr 25; 34(16):5644-50.
[Biochemistry. 1995]J Biol Chem. 2004 Jan 30; 279(5):3327-39.
[J Biol Chem. 2004]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D35-40.
[Nucleic Acids Res. 2004]